CN104324212A - Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof - Google Patents

Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof Download PDF

Info

Publication number
CN104324212A
CN104324212A CN201410691898.1A CN201410691898A CN104324212A CN 104324212 A CN104324212 A CN 104324212A CN 201410691898 A CN201410691898 A CN 201410691898A CN 104324212 A CN104324212 A CN 104324212A
Authority
CN
China
Prior art keywords
parts
chinese medicine
radix
medicine composition
otitis media
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410691898.1A
Other languages
Chinese (zh)
Inventor
邹士东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201410691898.1A priority Critical patent/CN104324212A/en
Publication of CN104324212A publication Critical patent/CN104324212A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A61K36/195—Strobilanthes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/238—Saposhnikovia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A61K36/315—Isatis, e.g. Dyer's woad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533—Leonurus (motherwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/638—Ligustrum, e.g. Chinese privet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/739—Sanguisorba (burnet)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8964—Anemarrhena
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8967—Lilium, e.g. tiger lily or Easter lily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention belongs to the field of medicines and relates to a traditional Chinese medicine composition for treating otitis media combined tinnitus. In order to overcome the defects in the prior art and relieve pain of otitis media patients, the invention provides a traditional Chinese medicine composition for treating otitis media combined tinnitus. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-12 parts of dandelion, 5-8 parts of honeysuckle, 6-9 parts of Divaricate Saposhnikovia Root, 3-5 parts of isatis root, 10-12 parts of garden burnet, 10-12 parts of motherwort, 3-5 parts of the root of bidentate achyranthes, 3-5 parts of rhizoma anemarrhenae, 10-12 parts of corydalis tuber, 8-10 parts of glossy privet fruit, 6-9 parts of the root of kudzu vine, 10-12 parts of teasel root, 10-12 parts of Polygonum multiflorum, 10-12 parts of lily, 12-15 parts of white paeony root and 9-12 parts of liquorice. The treatment medicine has obvious anti-inflammatory and analgesic activities, is obvious in curative effect, safe and reliable and has wide clinical application prospects.

Description

A kind of Chinese medicine composition and medical usage thereof for the treatment of otitis media and merging tinnitus
Technical field
The invention belongs to field of medicaments, relate to a kind of Chinese medicine composition and the medical usage thereof for the treatment of otitis media and merging tinnitus.
Background technology
Otitis media is modal a kind of disease, is mainly divided into apyetous and suppurative two large classes, cardinal symptom be suppurate, tinnitus and ear pain.Otitis media has multiple different pathogeny and symptom, and wherein acute and chronic catarrhal otitis media belongs to non-suppurative otitis media, and its symptom is: auditory dysesthesia, has deafness, tinnitus, in ear has current dynamic when certainly listening enhancing, head movement.Instrument inspection is visible, and otopiesis, incorrect marking is clear, limitation of activity, has pharyngeal bone vessel dysfunction.Common cold, throat infection all can cause that this is sick, acutely easily controls, and chronicly cannot effect a radical cure.The conventional treatments of otitis media is exactly drug administration, and the traditional Chinese medical science thinks that kidney governing bones marrow is had one's ideas straightened out in ear, and should be main from yin nourishing removing heat from the heart to restore the consciousness, with dispelling wind and heat pathogens, heat-clearing and detoxifying herb, with therapy of combining Chinese and Western medicine, effect be better.
At present, the otitis media Western medicine for the treatment of is a lot, but most drug therapeutic effect is poor, and treats into the shortcomings such as high, side effect is large in addition, even affects patient health time serious.In addition, also have the Chinese medicine of a lot for the treatment of otitis media, but great majority have the shortcomings such as the low and treatment cycle of therapeutic effect difference, cure rate is long.
Summary of the invention
In order to make up the deficiencies in the prior art, alleviate the misery of otitis media patient, it is evident in efficacy, safe and reliable to the invention provides a kind of Chinese medicine composition for the treatment of otitis media, has wide potential applicability in clinical practice.
Technical scheme of the present invention is:
Treat the Chinese medicine composition that otitis media merges tinnitus, this Chinese medicine composition is made up of the raw material of following weight portion: Herba Taraxaci 10-12 part, Flos Lonicerae 5-8 part, Radix Saposhnikoviae 6-9 part, Radix Isatidis 3-5 part, Radix Sanguisorbae 10-12 part, Herba Leonuri 10-12 part, Radix Achyranthis Bidentatae 3-5 part, Rhizoma Anemarrhenae 3-5 part, Rhizoma Corydalis 10-12 part, Fructus Ligustri Lucidi 8-10 part, Radix Puerariae 6-9 part, Radix Dipsaci 10-12 part, Radix Polygoni Multiflori 10-12 part, Bulbus Lilii 10-12 part, Radix Paeoniae Alba 12-15 part, Radix Glycyrrhizae 9-12 part.
In Chinese medicine composition described above, various Chinese medicinal components is all got its conventional agents area and is used as medicine.According to it, otitis media is merged to the therapeutic effect of tinnitus, described Chinese medicine composition is made up of the raw material of following weight portion: Herba Taraxaci 11 parts, Flos Lonicerae 7 parts, Radix Saposhnikoviae 7 parts, Radix Isatidis 4 parts, Radix Sanguisorbae 11 parts, Herba Leonuri 11 parts, Radix Achyranthis Bidentatae 4 parts, the Rhizoma Anemarrhenae 4 parts, Rhizoma Corydalis 11 parts, Fructus Ligustri Lucidi 9 parts, Radix Puerariae 8 parts, Radix Dipsaci 11 parts, Radix Polygoni Multiflori 11 parts, Bulbus Lilii 11 parts, the Radix Paeoniae Alba 13 parts, 10 parts, Radix Glycyrrhizae.
In Chinese medicine composition described above, Ramulus Cinnamomi 5-8 part magnolia obovata 12-15 part can also be contained.This in two Chinese medicine can strengthen the anti-inflammatory pain-stopping effect of the above-mentioned Chinese medicine composition of the present invention further.
The present invention also asks to protect the purposes of above-mentioned Chinese medicine composition in preparation treatment otitis media merging tinnitus medicine.Pharmaceutical composition of the present invention in the treatment otitis time, demonstrate remarkable anti-inflammatory and antalgic activity.Test examples 7 of the present invention shows, give positive drug and Chinese medicine composition of the present invention all can obtain significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have pole significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group significantly will be better than positive controls.Test examples 8 mice of the present invention licks foot response latency time showing, compare with model group, after administration after 1h and 2h, the incubation period that the mice of each administration group of Chinese medicine composition of the present invention adds foot reaction is all greater than model group, there is dose-dependence, and be significantly greater than model group (P < 0.05) incubation period of high dose group.What illustrate that this Chinese medicine composition of the present invention can extend that mice stimulates hot plate adds the sufficient response latency, has certain analgesic activity.Under same experiment condition, positive control drug cydiodine group (P < 0.05) and Radix Isatidis supernatant sheet group (1h, P < 0.05; 2h, P < 0.01) also extend the incubation period that mice adds foot reaction, there is certain analgesic activity, but its analgesic effect and model group there was no significant difference.
In order to express Chinese medicine composition of the present invention better, Chinese medicine composition of the present invention can be prepared into dosage form conventional clinically.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule, described pharmaceutical preparation all can prepare according to Chinese medicine preparation preparation method well-known to those skilled in the art.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into powder, water preparation, tablet or capsule.
Present invention also offers a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
The present invention is that inventor is through repeatedly studying, progressively improve, last successful a kind of curative effect treats the medicine of otitis media preferably, for showing that medicine of the present invention merges the therapeutic effect of tinnitus to otitis media, the present invention takes the otitis media merging tinnitus of this medicine patient to 180 examples has carried out clinical observation, and selects the otitis media with comparability to merge tinnitus patient 179 example as a control group.Treatment group patient takes medicine twice of the present invention every day, and sooner or later respectively once, once take 5 grams of medicines, matched group patient takes the oral drugs of conventional therapy otitis media.Treat after one month, therapeutic outcome is in table 1.
Table 1 treatment group and treatment of control group result synopsis
Cure Effectively Cure rate Effective percentage
Treatment group 141 examples 165 examples 78.33％ 91.67％
Matched group 93 examples 117 examples 51.96％ 65.36％
Treatment group is compared matched group and is had higher cure rate and effective percentage, thinks thus, and Drug therapy otitis media of the present invention has good effect, and through the Ureteral Calculus of month, takes medicine of the present invention and do not occur any toxic and side effects.
Chinese medicine composition of the present invention merges in tinnitus in treatment, compared with prior art has following advantage:
1) compared with the chemotherapeutic agent of Current therapeutic, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, and improves the quality of life of patient.
2) multi-medicament component is contained in Chinese medicine composition of the present invention, action target spot is numerous, pharmacological evaluation shows it and existing medicine has significant synergism in anti-inflammatory and antalgic, and significantly can reduce otitis media patient and occur tinnitus symptom, improve acceptance and the compliance of patient.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but those skilled in the art should know, described embodiment does not also limit the present invention in any way.
(1) example of formulations part
Embodiment 1 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Taraxaci 10 parts, Flos Lonicerae 5 parts, Radix Saposhnikoviae 6 parts, Radix Isatidis 3 parts, Radix Sanguisorbae 10 parts, Herba Leonuri 10 parts, Radix Achyranthis Bidentatae 3 parts, the Rhizoma Anemarrhenae 3 parts, Rhizoma Corydalis 10 parts, Fructus Ligustri Lucidi 8 parts, Radix Puerariae 6 parts, Radix Dipsaci 10 parts, Radix Polygoni Multiflori 10 parts, Bulbus Lilii 10 parts, the Radix Paeoniae Alba 12 parts, 9 parts, Radix Glycyrrhizae.
Get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, add according to 4 ~ 9 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40% ~ 95%, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
Embodiment 2 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Taraxaci 12 parts, Flos Lonicerae 8 parts, Radix Saposhnikoviae 9 parts, Radix Isatidis 5 parts, Radix Sanguisorbae 12 parts, Herba Leonuri 12 parts, Radix Achyranthis Bidentatae 5 parts, the Rhizoma Anemarrhenae 5 parts, Rhizoma Corydalis 12 parts, Fructus Ligustri Lucidi 10 parts, Radix Puerariae 9 parts, Radix Dipsaci 12 parts, Radix Polygoni Multiflori 12 parts, Bulbus Lilii 12 parts, the Radix Paeoniae Alba 15 parts, 12 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment 3 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Taraxaci 11 parts, Flos Lonicerae 7 parts, Radix Saposhnikoviae 7 parts, Radix Isatidis 4 parts, Radix Sanguisorbae 11 parts, Herba Leonuri 11 parts, Radix Achyranthis Bidentatae 4 parts, the Rhizoma Anemarrhenae 4 parts, Rhizoma Corydalis 11 parts, Fructus Ligustri Lucidi 9 parts, Radix Puerariae 8 parts, Radix Dipsaci 11 parts, Radix Polygoni Multiflori 11 parts, Bulbus Lilii 11 parts, the Radix Paeoniae Alba 13 parts, 10 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment 4 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Taraxaci 10 parts, Flos Lonicerae 5 parts, Radix Saposhnikoviae 6 parts, Radix Isatidis 3 parts, Radix Sanguisorbae 10 parts, Herba Leonuri 10 parts, Radix Achyranthis Bidentatae 3 parts, the Rhizoma Anemarrhenae 3 parts, Rhizoma Corydalis 10 parts, Fructus Ligustri Lucidi 8 parts, Radix Puerariae 6 parts, Radix Dipsaci 10 parts, Radix Polygoni Multiflori 10 parts, Bulbus Lilii 10 parts, the Radix Paeoniae Alba 12 parts, 9 parts, Radix Glycyrrhizae, Ramulus Cinnamomi 5 parts, Cortex Magnoliae Officinalis 13 parts
Preparation method is with embodiment 1.
Embodiment 5 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Taraxaci 12 parts, Flos Lonicerae 8 parts, Radix Saposhnikoviae 9 parts, Radix Isatidis 5 parts, Radix Sanguisorbae 12 parts, Herba Leonuri 12 parts, Radix Achyranthis Bidentatae 5 parts, the Rhizoma Anemarrhenae 5 parts, Rhizoma Corydalis 12 parts, Fructus Ligustri Lucidi 10 parts, Radix Puerariae 9 parts, Radix Dipsaci 12 parts, Radix Polygoni Multiflori 12 parts, Bulbus Lilii 12 parts, the Radix Paeoniae Alba 15 parts, 12 parts, Radix Glycyrrhizae, Ramulus Cinnamomi 8 parts, Cortex Magnoliae Officinalis 12 parts.
Preparation method is with embodiment 1.
Embodiment 6 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Herba Taraxaci 11 parts, Flos Lonicerae 7 parts, Radix Saposhnikoviae 7 parts, Radix Isatidis 4 parts, Radix Sanguisorbae 11 parts, Herba Leonuri 11 parts, Radix Achyranthis Bidentatae 4 parts, the Rhizoma Anemarrhenae 4 parts, Rhizoma Corydalis 11 parts, Fructus Ligustri Lucidi 9 parts, Radix Puerariae 8 parts, Radix Dipsaci 11 parts, Radix Polygoni Multiflori 11, Bulbus Lilii 11 parts, the Radix Paeoniae Alba 13 parts, 10 parts, Radix Glycyrrhizae, Ramulus Cinnamomi 6 parts, Cortex Magnoliae Officinalis 15 parts.
Preparation method is with embodiment 1.
(2) test examples part
The antiinflammatory action of embodiment 7 Chinese medicine composition xylol of the present invention induced mice inflammatory model
Hydrocortisone has stronger anti-inflammatory activity, be synthetic be also naturally occurring glucocorticoid, after hydrocortisone enters cell, activate cytoplasmic receptor, nucleus is entered after allosteric, be combined with DNA response element, cause suppression or the induction of genetic transcription, the expression of inflammation related proteins is changed.
1, experimental technique:
40 KM mices, male and female half and half, body weight 25-30 gram, four groups are divided at random, i.e. dosage group in model control group, combination group high dose group, compositions, compositions low dose group, positive controls by body weight, often organize 10, each administration group mice gives following medicine respectively:
Model control group: gavage gives the normal saline of same volume;
Positive controls: gavage gives the hydrocortisone drug solution of 5mg/kg;
Compositions high dose group: gavage gives 1000mg/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Dosage group in compositions: gavage gives 200mg/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Compositions low dose group: gavage gives 50mg/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Each administration group is administered once every day, successive administration 7d.Get dimethylbenzene 20 μ l after last administration, be applied to each mouse right ear.Get after 30 minutes and be respectively evenly applied to mouse right ear respectively by reagent 0.03ml, auris dextra is put to death after 3.5 hours to dimethylbenzene, measures each group of mice left and right ear method of double differences.Ear method of double differences assay method: place cuts two ears along auricle baseline, lays auricle with 8mm card punch at the same position of left and right ear, weighs, the ear method of double differences=auris dextra sheet weight-left auricle weight.The ear method of double differences can be used as evaluates antiinflammatory index.
2, experimental result:
Measure the antiphlogistic effects that each experimental mice ear method of double differences evaluates each medication group medicine.Measurement result is in table 1.
Table 1 each experimental mice ear method of double differences compares
Group n The ear method of double differences (mg)
Model control group 10 8.23±1.14
Positive controls 10 6.26±1.52 *
Compositions high dose group 10 2.84±1.82 **##
Dosage group in compositions 10 4.48±1.50 **#
Compositions low dose group 10 5.98±1.21 *
Compare with model control group, *p < 0.05; Compare with model control group, *p < 0.01;
Compare with positive controls, #p < 0.05; Compare with positive controls, ##p < 0.01.
Result display gives positive drug and Chinese medicine composition of the present invention all can obtain significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have pole significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group significantly will be better than positive controls.
Embodiment 8 Chinese medicine composition of the present invention affects mouse hot-plate analgesic
1 mouse hot-plate pain model makes
About body weight 20g female mice is placed on hot plate dolorimeter, screen qualified ♀ mice 90 (to lick metapedes time <5s or >30s to throw aside, scald for preventing foot, also deadline should be established, be generally 60s), the incubation period of metapedes reaction is added for threshold of pain index with mice, get 72 jennies, be divided into 6 groups, 12/group, i.e. model group, cydiodine, Radix Isatidis supernatant sheet group, Chinese medicine composition of the present invention (obtaining by Chinese medicine composition prescription described in embodiment 1 and preparation technology) low dose group, middle dosage group and high dose group.Each group is gastric infusion, and 1 times/day, dosage is as shown in table 10, and after successive administration 14d, after measuring last medicine, 60min, 120min add the time of foot reaction.
2 Chinese medicine compositions of the present invention are on the impact of licking the foot response latency in mouse hot-plate analgesic experiment
Mice licks foot response latency time showing, compare with model group, after administration after 1h and 2h, the incubation period that the mice of each administration group of Chinese medicine composition of the present invention adds foot reaction is all greater than model group, there is dose-dependence, and be significantly greater than model group (P < 0.05) incubation period of high dose group.What illustrate that this Chinese medicine composition of the present invention can extend that mice stimulates hot plate adds the sufficient response latency, has certain analgesic activity.Under same experiment condition, positive control drug cydiodine group (P < 0.05) and Radix Isatidis supernatant sheet group (1h, P < 0.05; 2h, P < 0.01) also extend the incubation period that mice adds foot reaction, there is certain analgesic activity, but its analgesic effect and model group there was no significant difference.The results are shown in Table 2.
Table 2 mice licks foot response latency timetable
Group Dosage (mg/kg) 1h(s) 2h(s)
Model group - 23.5±4.9 24.5±6.3
Hydrocortisone 150 25.5±9.9 26.1±7.9
Compositions low dose group 50 28.5±7.9* 31.1±7.8*
Dosage group in compositions 200 29.4±7.1* 32.4±10.4*
Compositions high dose group 1000 32.6±8.4* 34.5±7.8**
Note: compare with model group, * P < 0.05, * * P < 0.01.

Claims (7)

1. the Chinese medicine composition for the treatment of otitis media and merging tinnitus, it is characterized in that, it is made up of the raw material of following weight portion: Herba Taraxaci 10-12 part, Flos Lonicerae 5-8 part, Radix Saposhnikoviae 6-9 part, Radix Isatidis 3-5 part, Radix Sanguisorbae 10-12 part, Herba Leonuri 10-12 part, Radix Achyranthis Bidentatae 3-5 part, Rhizoma Anemarrhenae 3-5 part, Rhizoma Corydalis 10-12 part, Fructus Ligustri Lucidi 8-10 part, Radix Puerariae 6-9 part, Radix Dipsaci 10-12 part, Radix Polygoni Multiflori 10-12 part, Bulbus Lilii 10-12 part, Radix Paeoniae Alba 12-15 part, Radix Glycyrrhizae 9-12 part.
2. Chinese medicine composition as claimed in claim 1, is characterized in that, described Chinese medicine composition is also containing Ramulus Cinnamomi 5-8 part magnolia obovata 12-15 part.
3. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition is made up of the raw material of following weight portion: Herba Taraxaci 11 parts, Flos Lonicerae 7 parts, Radix Saposhnikoviae 7 parts, Radix Isatidis 4 parts, Radix Sanguisorbae 11 parts, Herba Leonuri 11 parts, Radix Achyranthis Bidentatae 4 parts, the Rhizoma Anemarrhenae 4 parts, Rhizoma Corydalis 11 parts, Fructus Ligustri Lucidi 9 parts, Radix Puerariae 8 parts, Radix Dipsaci 11 parts, Radix Polygoni Multiflori 11 parts, Bulbus Lilii 11 parts, the Radix Paeoniae Alba 13 parts, 10 parts, Radix Glycyrrhizae.
4. Chinese medicine composition as claimed in claim 4, is characterized in that, described Chinese medicine composition is also containing Ramulus Cinnamomi 5-8 part magnolia obovata 12-15 part.
5. Chinese medicine composition as claimed in claim 1 or 2, it is characterized in that, described Chinese medicine composition is powder, water preparation, tablet or capsule.
6. Chinese medicine composition as claimed in claim 1 or 2, it is characterized in that, the preparation method of described Chinese medicine composition comprises following step: get recipe quantity Chinese crude drug and be broken into coarse powder, adds according to 4 ~ 9 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40% ~ 95%, reflux, extract, three times, return time is 2 ~ 5h, filter, filtrate recycling ethanol, cold filtration, wash with water, after drying, namely obtain Chinese medical concrete; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
7. the Chinese medicine composition described in claim 1 or 2 merges the purposes in tinnitus medicine in preparation treatment otitis media.
CN201410691898.1A 2014-11-25 2014-11-25 Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof Pending CN104324212A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410691898.1A CN104324212A (en) 2014-11-25 2014-11-25 Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410691898.1A CN104324212A (en) 2014-11-25 2014-11-25 Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof

Publications (1)

Publication Number Publication Date
CN104324212A true CN104324212A (en) 2015-02-04

Family

ID=52399102

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410691898.1A Pending CN104324212A (en) 2014-11-25 2014-11-25 Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof

Country Status (1)

Country Link
CN (1) CN104324212A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108635572A (en) * 2018-07-30 2018-10-12 郑州兰茜生物工程有限公司 It is a kind of to treat otitis and the auristilla and preparation method thereof for ear function of feeling well with clear ear

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
房学贤，等: "《中西医结合眼耳鼻喉口齿科临床手册》", 31 January 2014 *
房学贤，等: "《历代疑难杂症方》", 30 June 1999 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108635572A (en) * 2018-07-30 2018-10-12 郑州兰茜生物工程有限公司 It is a kind of to treat otitis and the auristilla and preparation method thereof for ear function of feeling well with clear ear

Similar Documents

Publication Publication Date Title
CN102631579B (en) Oral Chinese herbal preparation for treating post-traumatic brain syndrome
CN101804189B (en) Drug for treating primary dysmenorrhea
CN103585591A (en) Traditional Chinese medicine for treating gallstones
CN103585545B (en) Traditional Chinese medicine composition for treating otitis media
CN104056177A (en) Traditional Chinese medicine composition for treating otitis media
CN103356932B (en) A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia
CN104337989A (en) Traditional Chinese medicine composition containing centipeda minima and frankincense for treating gout
CN104324212A (en) Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof
CN103705846A (en) Traditional Chinese medicine preparation for treating ovarian cyst
CN103550679A (en) Traditional Chinese medicine formula for treatment of lithangiuria
CN103948878B (en) A kind of Chinese medicine composition for the treatment of osteopathia
CN103432220B (en) Traditional Chinese medicine preparation for treating aching and preparation method thereof
CN101564483B (en) Liver smoothing for treating hyperplasia of mammary glands
CN104435545A (en) Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning
CN104547589A (en) Traditional Chinese medicine for treating polymyalgia rheumatica and applications of traditional Chinese medicine
CN103800664A (en) Traditional Chinese medicine composition for treating menopausal syndrome
CN103316291A (en) Anti acne of traditional Chinese medicine
CN104435629B (en) A kind of recurrent oral ulceration for the treatment of merges Chinese medicine of laryngopharynx swelling and pain and uses thereof
CN102764325B (en) Chinese medicinal composition for dispelling rheumatism and relieving pain
CN103536745A (en) Traditional Chinese medicinal watered pills for treating hyperplasia of mammary glands
Fan et al. Explore the rule and mechanism of psoriasis herbal treatment based on data mining and network pharmacology
CN105194088A (en) Traditional Chinese medicine preparation for treating cerebral apoplexy
CN104524100A (en) Application of traditional Chinese medicine composition in preparation of medicines for treating nasosinusitis combined with facial pain
CN104623256A (en) Traditional Chinese medicine composition for treating nasosinusitis
CN103655875B (en) Treatment blood sampling causes the medicine of Patients with Aplastic Anemia venous thrombosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150204